Maria Dung Cao1, Beathe Sitter1, Tone Frost Bathen1, Per E. Lnning2,3, Steinar Lundgren1,4, Ingrid Susann Gribbestad1
1Department of Circulation and Medical Imaging, Norwegian University of Science and Technology (NTNU), Trondheim, Norway; 2Department of Oncology, Haukeland University Hospital, Bergen, Norway; 3University of Bergen, Bergen, Norway; 4Department of Oncology, St.Olavs University Hospital, Trondheim, Norway
The presence and change in the composite choline signal detected in MR spectra has been suggested as a biomarker for breast cancer diagnosis and treatment monitoring. The purpose of this study was to evaluate quantitative changes in the level and composition of the choline-containing metabolites (tCho) prior to and after treatment with doxorubicin monotherapy in 30 patients with breast cancer. Our study suggests that quantitative changes in different choline profiles may be related to breast cancer treatment response.